Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Problems With Biomarkers: A Tale of Three Drugs

Executive Summary

Enthusiasm for biomarkers to guide drug development and clinical decision making is high, but given how little we know about them, biomarkers are a risky investment, as shown by experiences with EGFR inhibitors.

Related Content

Companion Diagnostics Move Toward Mainstream Drug Development
Companion Diagnostics Spark Pharma Deals, But Still Mostly For Cancer
What New Her2 Tests Say about Personalized Medicine
Biomarker Diagnostics: Place Your Bets Wisely
The Changing Dynamics of Cancer Drug Development
Hurry Up and Wait: The Slowdown in Accelerated Approvals
Risks and Rewards of Using Surrogates to Accelerate Commercialization
AstraZeneca's Iressa Problem
Targeted Therapeutics: Linking EGF Receptor Drugs to Diagnostics
Dako Ponders the Expanding Universe


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts